Takeda Pharmaceutical (TAK) executive reports sale of 20,363 ADS at $17.55

Rhea-AI Filing Summary

Takeda Pharmaceutical Co. Ltd. reported that Shannon Elaine Mary, Pres., Global Supply & Quality, sold 20,363 American Depositary Shares on 2026-08-11 in a sale categorized as an open market or private transaction at $17.55 per ADS. Following this sale, she directly holds 67,311 ADS.

Insider Trade Summary

Net Seller: 20,363 shares

Net Sell 1 txn

Insider Shannon Elaine Mary

Role Pres., Global Supply & Quality

Sold 20,363 shs ($357K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	20,363	$17.55	$357K

Holdings After Transaction: American Depositary Shares — 67,311 shares (Direct)

Key Figures

Shares sold: 20,363 ADS Sale price per ADS: $17.55 Shares held after transaction: 67,311 ADS +1 more

4 metrics

Shares sold 20,363 ADS American Depositary Shares sold on 2026-08-11

Sale price per ADS $17.55 Per-share price for the 20,363 ADS sale

Shares held after transaction 67,311 ADS Direct holdings following the 2026-08-11 sale

Net shares sold 20,363 ADS Net change in buy/sell activity in this report

Key Terms

American Depositary Shares, open market or private transaction, direct ownership

3 terms

American Depositary Shares financial

"The security title reported is American Depositary Shares."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

open market or private transaction financial

"The sale is described as a Sale in open market or private transaction."

direct ownership financial

"The transaction is coded as direct ownership following the sale."

FAQ

What insider transaction did TAK report for Shannon Elaine Mary?

Takeda Pharmaceutical (TAK) reported that Shannon Elaine Mary sold 20,363 American Depositary Shares on 2026-08-11. The transaction was recorded as an open market or private sale at $17.55 per ADS.

At what price were the Takeda (TAK) shares sold in this Form 4?

The reported transaction shows a sale price of $17.55 per American Depositary Share. This price is described as a per-share amount for the 20,363 ADS sold on 2026-08-11.

How many Takeda (TAK) shares does Shannon Elaine Mary hold after the sale?

After the reported sale, Shannon Elaine Mary directly holds 67,311 American Depositary Shares of Takeda Pharmaceutical. This figure reflects her post-transaction direct ownership as disclosed in the filing.

Was the Takeda (TAK) insider sale made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirming plan status, and no footnote indicates a trading plan. The sale is therefore not identified as pursuant to a Rule 10b5-1 plan in this disclosure.

What role does the insider in this Takeda (TAK) Form 4 hold?

The reporting person, Shannon Elaine Mary, serves as President, Global Supply & Quality at Takeda Pharmaceutical. The Form 4 links this executive officer role to the disclosed sale of American Depositary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 04:10 PM Accepted by SEC EDGAR 08/12/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shannon Elaine Mary

(Last) (First) (Middle)

45-55 HAYDEN AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres., Global Supply & Quality

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/11/2026		S		20,363	D	$17.55	67,311	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Samuel Ntonme, by power of attorney, for Elaine M. Shannon	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)